>

For a Safer, Healthier,
Cleaner World

Our vision is to transform humankind through fusion technology and its vast potential to create a safer, healthier, and cleaner world.

As today’s fusion company, we're deploying and scaling fusion technology now that we hope will one day lead to powering the world. Each step of the way, we're mastering more immediate applications of fusion – like inspecting industrial components through neutron imaging and producing cancer-fighting medicine. These applications create tremendous social and economic value and are the building blocks for our future goals: recycling nuclear waste and generating on-demand, carbon-free energy through fusion.

A word From Our Founder

We've chosen some of the most difficult things to do on Earth.

Greg Piefer, Founder and CEO
A word From Our Founder

We've chosen some of the most difficult things to do on Earth.

Greg Piefer, Founder and CEO

What We've Achieved

We've designed our four-phased approach to produce meaningful outcomes at each stage as we work toward fusion energy. As proud as we are of what we have accomplished already, we are even more excited about what's to come.

50 Trillion
we believe we hold the world record for a nuclear fusion reaction in a steady-state system, yielding about 50 trillion neutrons per second
1985
In 2023, we became the first non-utility to reach completion of the Nuclear Regulatory Commission’s technical review of an operating license application since 1985
20 Million
Once The Chrysalis is fully operational, we expect it to produce up to 20 million doses of molybdenum-99 per year
200,000
Cassiopeia – our large-scale lutetium-177 production facility – is expected to be capable of producing up to 200,000 doses per year
400
Our team consists of nearly 400 employees across divisions in the United States and Europe
A blue neutron beam
A blue neutron beam
50 Trillion
WE BELIEVE WE HOLD THE WORLD RECORD FOR A NUCLEAR FUSION REACTION IN A STEADY-STATE SYSTEM, YIELDING ABOUT 50 TRILLION NEUTRONS PER SECOND
1985
IN 2023, WE BECAME THE FIRST NON-UTILITY TO REACH COMPLETION OF THE NUCLEAR REGULATORY COMMISSION’S TECHNICAL REVIEW OF AN OPERATING LICENSE APPLICATION SINCE 1985
20 Million
ONCE THE CHRYSALIS IS FULLY OPERATIONAL, WE EXPECT IT TO PRODUCE UP TO 20 MILLION DOSES OF MOLYBDENUM-99 PER YEAR
200,000
CASSIOPEIA – OUR LARGE-SCALE LUTETIUM-177 PRODUCTION FACILITY – IS EXPECTED TO BE CAPABLE OF PRODUCING UP TO 200,000 DOSES PER YEAR
400
OUR TEAM CONSISTS OF NEARLY 400 EMPLOYEES ACROSS DIVISIONS IN THE UNITED STATES AND EUROPE

SHINE Europe

Veendam, the Netherlands is home to our European medical isotope production efforts. SHINE Europe will enhance our mission to bolster the nuclear medicine supply chain across the globe. Near-term, European efforts will focus on addressing urgent needs for therapeutic isotopes like lutetium-177. SHINE Europe has also been working since 2019 on plans for a production facility for diagnostic isotopes, like molybdenum-99, that would replicate the layout and production capacity of our Chrysalis facility. Additionally, in 2022, SHINE Europe announced the Dutch government approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.

Grounded in a
Scalable Approach

Developing revolutionary fusion technology throughout each of our four phases.

Four SHINE employees work together on a piece of technologyEmployees wearing PPE working in a radioisotope production area

Careers at SHINE: Let's Make History

Future generations will look back on the development of fusion technologies as a turning point in human history. We believe fusion will profoundly change the kinds of problems we can solve, elevate standards of living for all people, and achieve an unprecedented level of environmental harmony. Join our team and help us redefine what's possible.

Redefine What's Possible

We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.